Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanomaLisa Haas, Anna C. Obenauf, Maria Novatchkova et al.|Nature Cancer|2021Cited by 196
RSK1 Activation Promotes Invasion in Nodular MelanomaAmel Salhi, Iman Osman, Joshua A. Farhadian et al.|American Journal Of Pathology|2015Cited by 32
An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanomaJames P. Pham, Simone M. Goldinger, Ramon Staeger et al.|European Journal of Cancer|2024Cited by 12
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry studyLauren Brown, Benjamin Y. Kong, Victor Khou et al.|Frontiers in Oncology|2024Cited by 6